Royalty Pharma plc Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders
Royalty Pharma plc (RPRX) reported Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders of $131.75 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Shareholders' Equity › Noncontrolling Interest Items
us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders · last filed 2026-08-05
- Royalty Pharma plc noncontrolling interest, decrease from distributions to noncontrolling interest holders for the quarter ending 2026-06-30 was $131.75M, a 3.78% decline year-over-year.
- Royalty Pharma plc noncontrolling interest, decrease from distributions to noncontrolling interest holders for the quarter ending 2026-03-31 was $139.21M, a 18.80% decline year-over-year.
- Royalty Pharma plc noncontrolling interest, decrease from distributions to noncontrolling interest holders for the quarter ending 2025-12-31 was $116.86M, a 6.91% increase year-over-year.
- Royalty Pharma plc noncontrolling interest, decrease from distributions to noncontrolling interest holders for the quarter ending 2025-09-30 was $116.03M, a 2.51% increase year-over-year.
- Royalty Pharma plc noncontrolling interest, decrease from distributions to noncontrolling interest holders for fiscal 2025 was $541.26M, a 13.56% increase from fiscal 2024.
- Royalty Pharma plc noncontrolling interest, decrease from distributions to noncontrolling interest holders for fiscal 2024 was $476.63M, a 2.27% decline from fiscal 2023.
- Royalty Pharma plc noncontrolling interest, decrease from distributions to noncontrolling interest holders for fiscal 2023 was $487.72M, a 19.28% decline from fiscal 2022.
- Royalty Pharma plc noncontrolling interest, decrease from distributions to noncontrolling interest holders for fiscal 2022 was $604.25M, a 1.74% decline from fiscal 2021.
| Period end | Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders 3 month | Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders 6 month | Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders 9 month | Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders 12 month |
|---|---|---|---|---|
| 2026-06-30 | $131.75M 10-Q · filed 2026-08-05 | $270.96M 10-Q · filed 2026-08-05 | $387.83M derived: sum of 3 quarters · filed 2026-08-05 | $503.85M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $139.21M 10-Q · filed 2026-05-06 | $256.07M derived: sum of 2 quarters · filed 2026-05-06 | $372.10M derived: sum of 3 quarters · filed 2026-05-06 | $509.03M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $116.86M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $232.89M derived: sum of 2 quarters · filed 2026-02-11 | $369.82M derived: sum of 3 quarters · filed 2026-08-05 | $541.26M 10-K · filed 2026-02-11 |
| 2025-09-30 | $116.03M 10-Q · filed 2025-11-05 | $252.96M derived: sum of 2 quarters · filed 2026-08-05 | $424.40M 10-Q · filed 2025-11-05 | $533.71M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $136.93M 10-Q · filed 2026-08-05 | $308.37M 10-Q · filed 2026-08-05 | $417.68M derived: sum of 3 quarters · filed 2026-08-05 | $530.87M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $171.44M 10-Q · filed 2026-05-06 | $280.75M derived: sum of 2 quarters · filed 2026-05-06 | $393.94M derived: sum of 3 quarters · filed 2026-05-06 | $523.66M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $109.31M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $222.49M derived: sum of 2 quarters · filed 2026-02-11 | $352.22M derived: sum of 3 quarters · filed 2026-02-11 | $476.63M 10-K · filed 2026-02-11 |
| 2024-09-30 | $113.18M 10-Q · filed 2025-11-05 | $242.91M derived: sum of 2 quarters · filed 2025-11-05 | $367.32M 10-Q · filed 2025-11-05 | $468.45M derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-06-30 | $129.73M 10-Q · filed 2025-08-06 | $254.14M 10-Q · filed 2025-08-06 | $355.27M derived: sum of 3 quarters · filed 2026-02-11 | $475.47M derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-03-31 | $124.41M 10-Q · filed 2025-05-08 | $225.54M derived: sum of 2 quarters · filed 2026-02-11 | $345.74M derived: sum of 3 quarters · filed 2026-02-11 | $483.02M derived: sum of 4 quarters · filed 2026-02-11 |
| 2023-12-31 | $101.13M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $221.33M derived: sum of 2 quarters · filed 2026-02-11 | $358.61M derived: sum of 3 quarters · filed 2026-02-11 | $487.72M 10-K · filed 2026-02-11 |
| 2023-09-30 | $120.20M 10-Q · filed 2024-11-06 | $257.48M derived: sum of 2 quarters · filed 2024-11-06 | $386.59M 10-Q · filed 2024-11-06 | $557.02M derived: sum of 4 quarters · filed 2025-02-12 |
| 2023-06-30 | $137.28M 10-Q · filed 2024-08-08 | $266.39M 10-Q · filed 2024-08-08 | $436.82M derived: sum of 3 quarters · filed 2025-02-12 | $574.70M derived: sum of 4 quarters · filed 2025-02-12 |
| 2023-03-31 | $129.11M 10-Q · filed 2024-05-09 | $299.54M derived: sum of 2 quarters · filed 2025-02-12 | $437.42M derived: sum of 3 quarters · filed 2025-02-12 | $584.38M derived: sum of 4 quarters · filed 2025-02-12 |
| 2022-12-31 | $170.43M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-12 | $308.31M derived: sum of 2 quarters · filed 2025-02-12 | $455.27M derived: sum of 3 quarters · filed 2025-02-12 | $604.25M 10-K · filed 2025-02-12 |
| 2022-09-30 | $137.88M 10-Q · filed 2023-11-08 | $284.85M derived: sum of 2 quarters · filed 2023-11-08 | $433.82M 10-Q · filed 2023-11-08 | $572.89M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-06-30 | $146.97M 10-Q · filed 2023-08-08 | $295.94M 10-Q · filed 2023-08-08 | $435.01M derived: sum of 3 quarters · filed 2024-02-15 | $594.73M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-03-31 | $148.98M 10-Q · filed 2023-05-09 | $288.05M derived: sum of 2 quarters · filed 2024-02-15 | $447.76M derived: sum of 3 quarters · filed 2024-02-15 | $618.57M derived: sum of 4 quarters · filed 2024-02-15 |
| 2021-12-31 | $139.07M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $298.79M derived: sum of 2 quarters · filed 2024-02-15 | $469.59M derived: sum of 3 quarters · filed 2024-02-15 | $614.97M 10-K · filed 2024-02-15 |
| 2021-09-30 | $159.71M 10-Q · filed 2022-11-08 | $330.52M derived: sum of 2 quarters · filed 2022-11-08 | $475.90M 10-Q · filed 2022-11-08 | $716.63M derived: sum of 4 quarters · filed 2023-02-15 |
| 2021-06-30 | $170.81M 10-Q · filed 2022-08-04 | $316.19M 10-Q · filed 2022-08-04 | $556.92M derived: sum of 3 quarters · filed 2023-02-15 | $732.27M derived: sum of 4 quarters · filed 2023-02-15 |
| 2021-03-31 | $145.38M 10-Q · filed 2022-05-05 | $386.11M derived: sum of 2 quarters · filed 2023-02-15 | $561.46M derived: sum of 3 quarters · filed 2023-02-15 | $857.94M derived: sum of 4 quarters · filed 2023-02-15 |
| 2020-12-31 | $240.73M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-15 | $416.08M derived: sum of 2 quarters · filed 2023-02-15 | $712.56M derived: sum of 3 quarters · filed 2023-02-15 | $1.11B 10-K · filed 2023-02-15 |
| 2020-09-30 | $175.35M 10-Q · filed 2021-11-10 | $471.83M derived: sum of 2 quarters · filed 2021-11-10 | $865.03M 10-Q · filed 2021-11-10 | $1.07B derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-06-30 | $296.48M 10-Q · filed 2021-08-11 | $689.68M 10-Q · filed 2021-08-11 | $897.46M derived: sum of 3 quarters · filed 2022-02-15 | $1.09B derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-03-31 | $393.20M 10-Q · filed 2021-05-11 | $600.98M derived: sum of 2 quarters · filed 2022-02-15 | $797.72M derived: sum of 3 quarters · filed 2022-02-15 | $1.03B derived: sum of 4 quarters · filed 2022-02-15 |
| 2019-12-31 | $207.77M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-15 | $404.51M derived: sum of 2 quarters · filed 2022-02-15 | $638.05M derived: sum of 3 quarters · filed 2022-02-15 | $880.14M 10-K · filed 2022-02-15 |
| 2019-09-30 | $196.74M 10-Q · filed 2020-11-12 | $430.27M derived: sum of 2 quarters · filed 2020-11-12 | $672.37M 10-Q · filed 2020-11-12 | |
| 2019-06-30 | $233.53M 10-Q · filed 2020-08-12 | $475.63M 10-Q · filed 2020-08-12 | ||
| 2018-12-31 | $1.03B 10-K · filed 2021-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |